Dr. Apolo on Toxicity Challenges With Checkpoint Inhibitors in Bladder Cancer

Andrea B. Apolo, MD
Published: Wednesday, Dec 20, 2017



Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses challenges with managing toxicities of checkpoint inhibitors for patients with bladder cancer.

It is important to be thorough when evaluating patients who are receiving immune checkpoint inhibitors. Being aggressive in evaluating symptoms is important because many toxicities associated with checkpoint inhibitors can be severe, explains Apolo.
 


Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses challenges with managing toxicities of checkpoint inhibitors for patients with bladder cancer.

It is important to be thorough when evaluating patients who are receiving immune checkpoint inhibitors. Being aggressive in evaluating symptoms is important because many toxicities associated with checkpoint inhibitors can be severe, explains Apolo.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x